Testsealabs CEA Carcinoembryonic Antigen Test
Short Description:
Fast & Accurate：Achieve reliable results in minutes.
Simple Operation：No complex equipment required.
High Accuracy：Lab-grade precision you can trust.
Clear Visual Readout：Results are easy to read and interpret.
Certified Quality Systems：Compliant with ISO 13485 and MDSAP.
Room-Temperature Stability：No cold chain needed—easy to transport and store.
Product Specification
| Principle | Chromatographic Immunoassay | Specimen | Whole Blood/Serum/Plasma |
| Reading Time | 5 minutes | QMS Certification | ISO 13485 and MDSAP |
| Storage Temperature | 4-30°C | Shelf life | 2 years |
| Format | Cassette | Specification | 25T/40T |
Intended Use
The CEA Carcinoembryonic Antigen Test is a rapid chromatographic immunoassay for the qualitative detection of CEA in whole blood, serum or plasma to aid in monitoring of cancer patients.
Summary
Carcinoembryonic antigen (CEA) is a cell surface glycoprotein of approximately 20,000 molecular weight. Further investigations showed that CEA can presence in a variety of cancers other than colonic, including pancreatic, gastric, lung, and breast etc. Small amounts have also been demonstrated in secretions from the colonic mucosa. Persistent elevation in circulating CEA following treatment is strongly indicative of occult metastatic and/or residual disease. A persistent rising CEA value may be associated with progressive malignant disease and poor therapeutic response. A declining CEA value is generally indicative of a favorable prognosis and good response to treatment. Measurement of CEA has been shown to be clinically relevant in the follow-up management of patients with colorectal, breast, lung, prostatic, pancreatic, ovarian, and other carcinomas. Follow-up studies of patients with colorectal, breast and lung carcinomas suggest that the preoperative CEA level has prognostic significance. CEA testing is not recommended as a screening procedure to detect cancer in the general population; however, use of the CEA test as an adjunctive test in the prognosis and management of cancer patients is widely accepted. The minimum detection level is 5 ng/mL.
